Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul-Aug;47(4):436-9.
doi: 10.4103/0253-7613.161272.

Short and long-term impact of pharmacovigilance training on the pharmacovigilance knowledge of medical students

M Aylin Arici  1 , Ayse Gelal  1 , Yucel Demiral  2 , Yesim Tuncok  1
Affiliations

Short and long-term impact of pharmacovigilance training on the pharmacovigilance knowledge of medical students

M Aylin Arici et al. Indian J Pharmacol. 2015 Jul-Aug.

Abstract

Objectives: The aim of this study was to evaluate the short and long-term impact of pharmacovigilance (PV) training on the 5th year medical students' knowledge about definitions and on the awareness of the regulatory aspects in PV.

Materials and methods: In academic year 2010/11, the students completed structured, questionnaire before and just after training. They also completed the same questionnaire 1-year after the training.

Results: The students' knowledge about PV significantly increased after training in the short term (P < 0.001). However, the improvement decreased significantly in the long-term (P < 0.001). Although long-term scores were higher than the baseline score, the difference was not statistically significant. Total scores were 17.5 ± 2.0, 20.8 ± 2.0 and 18.0 ± 2.5; before, at short and long-term after the training.

Conclusion: PV training increased the students' knowledge significantly. However, in the long-term, the impact of the training is limited. Repeated training of PV should be planned.

Keywords: Awareness; impact; knowledge; medical training; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No.

References

    1. Geneva: WHO; 2004. [Last accessed on 2014 Apr 10]. World Health Organization. WHO Policy Perspectives on Medicines. Looking at the Pharmacovigilance: Ensuring the Safe Use of Medicines. Available from: http://www.whqlibdoc.who.int/hq/2004/WHO_EDM_2004.8.pdf/
    1. Guide for the Monitorization and Evaluation of the Medicinal Products. Published in Official Gazete in 30th March, 2005 to Became Valid 30th June. 2005. [Last accessed on 2014 Apr 10]. Available from: http://www.rega.basbakanlik.gov.tr/
    1. Begum SS, Mansoor M, Sandeep A, Mahadevamma L, Krishnagoudar BS. Tools to improve reporting of adverse drug reactions – A review. Int J Pharm Sci Rev Res. 2013;23:262–5.
    1. Chopra D, Wardhan N, Rehan HS. Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital. Int J Risk Saf Med. 2011;23:227–32. - PubMed
    1. Gupta P, Udupa A. Adverse drug reaction reporting and pharmacovigilance: Knowledge, attitudes and perceptions amongst resident doctors. J Pharm Sci Res. 2011;3:1064–9.